These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29568566)

  • 1. Could dietary glutamate be contributing to the symptoms of obsessive-compulsive disorder?
    Holton KF; Cotter EW
    Future Sci OA; 2018 Mar; 4(3):FSO277. PubMed ID: 29568566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms.
    Holton KF; Taren DL; Thomson CA; Bennett RM; Jones KD
    Clin Exp Rheumatol; 2012; 30(6 Suppl 74):10-7. PubMed ID: 22766026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
    Murphy TK; Brennan EM; Johnco C; Parker-Athill EC; Miladinovic B; Storch EA; Lewin AB
    J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):640-651. PubMed ID: 28358599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher prevalence of irritable bowel syndrome and greater gastrointestinal symptoms in obsessive-compulsive disorder.
    Turna J; Grosman Kaplan K; Patterson B; Bercik P; Anglin R; Soreni N; Van Ameringen M
    J Psychiatr Res; 2019 Nov; 118():1-6. PubMed ID: 31437616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
    Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH
    CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
    Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
    Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
    Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mindfulness-based cognitive therapy (MBCT) in patients with obsessive-compulsive disorder (OCD) and residual symptoms after cognitive behavioral therapy (CBT): a randomized controlled trial.
    Külz AK; Landmann S; Cludius B; Rose N; Heidenreich T; Jelinek L; Alsleben H; Wahl K; Philipsen A; Voderholzer U; Maier JG; Moritz S
    Eur Arch Psychiatry Clin Neurosci; 2019 Mar; 269(2):223-233. PubMed ID: 30446822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
    Zohar J; Insel TR
    Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabis Improves Obsessive-Compulsive Disorder-Case Report and Review of the Literature.
    Szejko N; Fremer C; Müller-Vahl KR
    Front Psychiatry; 2020; 11():681. PubMed ID: 32848902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between obsessive compulsive disorder and obsessive compulsive personality disorder: prevalence and clinical presentation.
    Gordon OM; Salkovskis PM; Oldfield VB; Carter N
    Br J Clin Psychol; 2013 Sep; 52(3):300-15. PubMed ID: 23865406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial.
    Sabetnejad Z; Assarian F; Omidi A; Najarzadegan MR
    Electron Physician; 2016 Nov; 8(11):3156-3163. PubMed ID: 28070247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
    Jahanbakhsh SP; Manteghi AA; Emami SA; Mahyari S; Gholampour B; Mohammadpour AH; Sahebkar A
    Complement Ther Med; 2016 Aug; 27():25-9. PubMed ID: 27515872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Gonadal Hormones on Neurotransmitters Implicated in the Pathophysiology of Obsessive-Compulsive Disorder: A Critical Review.
    Karpinski M; Mattina GF; Steiner M
    Neuroendocrinology; 2017; 105(1):1-16. PubMed ID: 27894107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models of obsessive compulsive disorder: recent findings and future directions.
    Hoffman KL
    Expert Opin Drug Discov; 2011 Jul; 6(7):725-37. PubMed ID: 22650979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.